comparemela.com

Latest Breaking News On - Belev - Page 3 : comparemela.com

Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Significant Drop in Short Interest

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totalling 1,320,000 shares, a drop of 11.4% from the June 30th total of 1,490,000 shares. Based on an average daily volume of 1,940,000 shares, the short-interest ratio […]

Blackrock-inc
Millennium-management
Nasdaq
Elevation-oncology-inc
Jpmorgan-chase-co
Virtu-financial
Renaissance-technologies
Elevation-oncology
Get-free-report
Oncology-stock-down
Elevation-oncology-daily

BML Capital Management LLC Makes New Investment in Elevation Oncology, Inc. (NASDAQ:ELEV)

BML Capital Management LLC bought a new position in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 39,963 shares of the company’s stock, valued at approximately $38,000. Elevation Oncology accounts for 0.0% […]

United-states
Nasdaq
Millennium-management
Elevation-oncology-inc
Bml-capital-management
Annandale-capital
Virtu-financial
Blackrock-inc
Renaissance-technologies
Exchange-commission
Capital-management

Elevation Oncology (NASDAQ:ELEV) Upgraded at SVB Securities

SVB Securities upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a report issued on Tuesday, The Fly reports. SVB Securities currently has $8.00 target price on the stock, up from their previous target price of $5.00. Separately, Wedbush reiterated an outperform rating and set […]

United-states
Elevation-oncology-company-profile
Elevation-oncology-inc
Tang-capital-management
Sio-capital-management
Renaissance-technologies
Geode-capital-management
Elevation-oncology
Get-rating
Moderate-buy
Oncology-stock-down

Elevation Oncology (NASDAQ:ELEV) Upgraded at SVB Leerink

SVB Leerink upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a research report report published on Tuesday morning, PriceTargets.com reports. A number of other analysts have also recently issued reports on ELEV. Wedbush restated an outperform rating and set a $4.00 price objective on […]

United-states
Tang-capital-management
Elevation-oncology-inc
Sio-capital-management
Geode-capital-management
Renaissance-technologies
Elevation-oncology
Get-rating
Moderate-buy
Oncology-stock-down
Capital-management

Elevation Oncology (NASDAQ:ELEV) Lifted to Outperform at SVB Securities

SVB Securities upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a report released on Tuesday morning, The Fly reports. They currently have $8.00 price objective on the stock, up from their previous price objective of $5.00. Separately, Wedbush reaffirmed an outperform rating and issued […]

United-states
Geode-capital-management
Sio-capital-management
Renaissance-technologies
Tang-capital-management
Elevation-oncology-inc
Elevation-oncology
Get-rating
Moderate-buy
Capital-management
Sigma-investments

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.